This is the authors' abstract. We don't add key points for this paper.
The development of a new treatment typically involves evaluation of its efficacy in a large clinical trial in which patients are randomly assigned either the new treatment or the standard of care. Results from these large randomized clinical trials allow for a definitive and unbiased assessment of the clinical benefit of the new treatment over the standard one. For rare diseases or for small patient subgroups identified within the context of a common disease, it may not be possible to conduct a large randomized trial. In this Review, we discuss alternative clinical study designs and statistical challenges that arise when attempting to assure that study results yield robust conclusions about the safety and effectiveness of a new medical product.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Korn et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: